UroGen Pharma Ltd. CEO Elizabeth Barrett's 2020 pay falls 90% to $2.5M
UroGen Pharma Ltd. reports 2020 executive compensation
By ExecPay News
Published: April 28, 2021
UroGen Pharma Ltd. reported fiscal year 2020 executive compensation information on April 28, 2021.
In 2020, six executives at UroGen Pharma Ltd. received on average a compensation package of $1.4M, a 76% decrease compared to previous year.
Average pay of disclosed executives at UroGen Pharma Ltd.
Elizabeth Barrett, Chief Executive Officer, received $2.5M in total, which decreased by 90% compared to 2019. 36% of Barrett's compensation, or $876K, was in option awards. Barrett also received $469K in non-equity incentive plan, $637K in salary, $441K in stock awards, as well as $44K in other compensation.
For fiscal year 2020, the median employee pay was $222,109 at UroGen Pharma Ltd.. Therefore, the ratio of Elizabeth Barrett's pay to the median employee pay was 11 to one.
Jason Smith, General Counsel, received a compensation package of $1.6M. 49% of the compensation package, or $785K, was in option awards.
Molly Henderson, Chief Financial Officer, earned $1.4M in 2020.
Peter P. Pfreundschuh, Chief Financial Officer, received $1.2M in 2020, which decreases by 14% compared to 2019.
Mark Schoenberg, Chief Medical Officer, earned $948K in 2020, a 18% increase compared to previous year.
Stephen Mullennix, Chief Operating Officer, received $906K in 2020, which decreases by 33% compared to 2019.
Related executives
Elizabeth Barrett
UroGen Pharma Ltd.
Chief Executive Officer
Molly Henderson
UroGen Pharma Ltd.
Chief Financial Officer
Peter Pfreundschuh
UroGen Pharma Ltd.
Chief Financial Officer
Stephen Mullennix
UroGen Pharma Ltd.
Chief Operating Officer
Mark Schoenberg
UroGen Pharma Ltd.
Chief Medical Officer
Jason Smith
UroGen Pharma Ltd.
General Counsel
You may also like
Source: SEC filing on April 28, 2021.